Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data - touchNEUROLOGY
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
Eva Kubala Havrdová - Proč nepodléhat strachu | RS kompas
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis | NEJM
Clinical Advances in MS: Changing the Future for Patients
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Untitled
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate_ Experiences of an international
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Prezentace aplikace PowerPoint
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges - Angelo Ghezzi, Maria Pia Amato, Gilles Edan, Hans-Peter Hartung, Eva Kubala Havrdová, Ludwig Kappos, Xavier Montalban, Carlo Pozzilli,
Treatment sequencing in multiple sclerosis: The benefits of disease-modifying therapies - touchNEUROLOGY
PDF) Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study – ScienceOpen
Efficacy and Safety of Ozanimod in the Blinded Extension (120 weeks) of RADIANCE Part A, a Phase 2 Trial in Relapsing Multiple S
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study | PLOS ONE
Eva Kubala Havrdová - Proč nepodléhat strachu | RS kompas
Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes
